Search results
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 16 hours agoModerna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine...
Moderna makes several cost-cutting moves, leans into AI - Boston Business Journal
The Business Journals· 12 hours agoAs Moderna Inc. works toward expanding its approved products beyond its Covid-19 vaccine, the...
Moderna Beats Quarterly Estimates as Cost-Cutting Pares Losses
Bloomberg· 16 hours agoModerna Inc. reported a narrower first-quarter loss than Wall Street had expected, as the biotech...
J.P. Morgan downgrades Metagenomi over Moderna deal termination (NASDAQ:MGX)
Seeking Alpha· 8 hours agoJ.P. Morgan has lowered its rating of Metagenomi (NASDAQ:MGX) to neutral, citing the recent...
Why Earnings Season Could Be Great for Moderna (MRNA)
Zacks via Yahoo Finance· 1 day agoInvestors are always looking for stocks that are poised to beat at earnings season and Moderna, Inc....
Moderna quarterly sales beat expectations but plummet from previous year
Reuters via Yahoo Finance· 16 hours agoModerna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was ...
Moderna, Carvana and Peloton rise premarket; DoorDash, Fastly, Zillow fall By Investing.com
Investing.com· 14 hours agoModerna, Carvana and Peloton rise premarket; DoorDash, Fastly, Zillow fall
Moderna Inc (MRNA) Q1 2024 Earnings: Significant Revenue Decline
Guru Focus· 19 hours agoOn May 2, 2024, Moderna Inc (MRNA, Financial) released its 8-K filing, disclosing a challenging first quarter with total revenues of $167 million, a stark decline from $1.9 ...
Moderna Inc (MRNA)'s Uncertain Future: Understanding the Barrier
Guru Focus· 8 hours agoLong-established in the Biotechnology industry, Moderna Inc (MRNA, Financial) has enjoyed a stellar reputation. Notably, its diminished rankings in financial strength, growth ...
Moderna Quarterly Sales Beat Expectations but Plummet From Previous Year
US News & World Report· 16 hours agoSales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed analysts’ expectations ...